A Novel Diagnostic Biomarker, PZP, for Detecting Colorectal Cancer in Type 2 Diabetes Mellitus Patients Identified by Serum-Based Mass Spectrometry

Background: Growing evidence has confirmed that populations with type 2 diabetes mellitus (T2DM) have an increasing risk of developing colorectal cancer (CRC). Thus, convenient and effective screening strategies for CRC should be developed for the T2DM population to increase the detection rate of CR...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jiayue Yang, Weigang Fang, Wenjun Wu, Zhen Tian, Rong Gao, Lu Yu, Dayang Chen, Xiaohua Weng, Shengwei Zhu, Cheng Yang
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
PZP
Acceso en línea:https://doaj.org/article/7b7d3051e1494d88a55880349c2c8e84
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:7b7d3051e1494d88a55880349c2c8e84
record_format dspace
spelling oai:doaj.org-article:7b7d3051e1494d88a55880349c2c8e842021-12-01T19:28:05ZA Novel Diagnostic Biomarker, PZP, for Detecting Colorectal Cancer in Type 2 Diabetes Mellitus Patients Identified by Serum-Based Mass Spectrometry2296-889X10.3389/fmolb.2021.736272https://doaj.org/article/7b7d3051e1494d88a55880349c2c8e842021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fmolb.2021.736272/fullhttps://doaj.org/toc/2296-889XBackground: Growing evidence has confirmed that populations with type 2 diabetes mellitus (T2DM) have an increasing risk of developing colorectal cancer (CRC). Thus, convenient and effective screening strategies for CRC should be developed for the T2DM population to increase the detection rate of CRC.Methods: Twenty serum samples extracted from five healthy participants, five T2DM patients, five CRC patients and five T2DM patients with CRC (T2DM + CRC) were submitted to data-independent acquisition mass spectrometry (DIA-MS) analysis to discover unique differentially altered proteins (DAPs) for CRC in patients with T2DM. Then, the diagnostic value of pregnancy zone protein (PZP) was validated by ELISA analysis in the validated cohort.Results: Based on DIA-MS analysis, we found eight unique proteins specific to T2DM patients with CRC. Among these proteins, four proteins showed different expression between the T2DM + CRC and T2DM groups, and PZP exhibited the largest difference. Next, the diagnostic value of serum PZP was validated by ELISA analysis with an AUC of 0.713. Moreover, the combination of PZP, CA199 and CEA exhibited encouraging diagnostic value, and the AUC reached 0.916.Conclusion: Overall, our current research implied that PZP could be regarded as a newfound serum biomarker for CRC medical diagnosis in T2DM patients.Jiayue YangWeigang FangWenjun WuZhen TianRong GaoLu YuDayang ChenXiaohua WengShengwei ZhuCheng YangFrontiers Media S.A.articlebiomarkercolorectal cancertype 2 diabetes mellitusmass spectrumPZPBiology (General)QH301-705.5ENFrontiers in Molecular Biosciences, Vol 8 (2021)
institution DOAJ
collection DOAJ
language EN
topic biomarker
colorectal cancer
type 2 diabetes mellitus
mass spectrum
PZP
Biology (General)
QH301-705.5
spellingShingle biomarker
colorectal cancer
type 2 diabetes mellitus
mass spectrum
PZP
Biology (General)
QH301-705.5
Jiayue Yang
Weigang Fang
Wenjun Wu
Zhen Tian
Rong Gao
Lu Yu
Dayang Chen
Xiaohua Weng
Shengwei Zhu
Cheng Yang
A Novel Diagnostic Biomarker, PZP, for Detecting Colorectal Cancer in Type 2 Diabetes Mellitus Patients Identified by Serum-Based Mass Spectrometry
description Background: Growing evidence has confirmed that populations with type 2 diabetes mellitus (T2DM) have an increasing risk of developing colorectal cancer (CRC). Thus, convenient and effective screening strategies for CRC should be developed for the T2DM population to increase the detection rate of CRC.Methods: Twenty serum samples extracted from five healthy participants, five T2DM patients, five CRC patients and five T2DM patients with CRC (T2DM + CRC) were submitted to data-independent acquisition mass spectrometry (DIA-MS) analysis to discover unique differentially altered proteins (DAPs) for CRC in patients with T2DM. Then, the diagnostic value of pregnancy zone protein (PZP) was validated by ELISA analysis in the validated cohort.Results: Based on DIA-MS analysis, we found eight unique proteins specific to T2DM patients with CRC. Among these proteins, four proteins showed different expression between the T2DM + CRC and T2DM groups, and PZP exhibited the largest difference. Next, the diagnostic value of serum PZP was validated by ELISA analysis with an AUC of 0.713. Moreover, the combination of PZP, CA199 and CEA exhibited encouraging diagnostic value, and the AUC reached 0.916.Conclusion: Overall, our current research implied that PZP could be regarded as a newfound serum biomarker for CRC medical diagnosis in T2DM patients.
format article
author Jiayue Yang
Weigang Fang
Wenjun Wu
Zhen Tian
Rong Gao
Lu Yu
Dayang Chen
Xiaohua Weng
Shengwei Zhu
Cheng Yang
author_facet Jiayue Yang
Weigang Fang
Wenjun Wu
Zhen Tian
Rong Gao
Lu Yu
Dayang Chen
Xiaohua Weng
Shengwei Zhu
Cheng Yang
author_sort Jiayue Yang
title A Novel Diagnostic Biomarker, PZP, for Detecting Colorectal Cancer in Type 2 Diabetes Mellitus Patients Identified by Serum-Based Mass Spectrometry
title_short A Novel Diagnostic Biomarker, PZP, for Detecting Colorectal Cancer in Type 2 Diabetes Mellitus Patients Identified by Serum-Based Mass Spectrometry
title_full A Novel Diagnostic Biomarker, PZP, for Detecting Colorectal Cancer in Type 2 Diabetes Mellitus Patients Identified by Serum-Based Mass Spectrometry
title_fullStr A Novel Diagnostic Biomarker, PZP, for Detecting Colorectal Cancer in Type 2 Diabetes Mellitus Patients Identified by Serum-Based Mass Spectrometry
title_full_unstemmed A Novel Diagnostic Biomarker, PZP, for Detecting Colorectal Cancer in Type 2 Diabetes Mellitus Patients Identified by Serum-Based Mass Spectrometry
title_sort novel diagnostic biomarker, pzp, for detecting colorectal cancer in type 2 diabetes mellitus patients identified by serum-based mass spectrometry
publisher Frontiers Media S.A.
publishDate 2021
url https://doaj.org/article/7b7d3051e1494d88a55880349c2c8e84
work_keys_str_mv AT jiayueyang anoveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry
AT weigangfang anoveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry
AT wenjunwu anoveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry
AT zhentian anoveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry
AT ronggao anoveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry
AT luyu anoveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry
AT dayangchen anoveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry
AT xiaohuaweng anoveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry
AT shengweizhu anoveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry
AT chengyang anoveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry
AT jiayueyang noveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry
AT weigangfang noveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry
AT wenjunwu noveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry
AT zhentian noveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry
AT ronggao noveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry
AT luyu noveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry
AT dayangchen noveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry
AT xiaohuaweng noveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry
AT shengweizhu noveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry
AT chengyang noveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry
_version_ 1718404639789940736